Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

AGS-003

Dendritic cell Immunotherapeutic

DRUG

Sunitinib

An approved drug for the treatment of RCC

Trial Locations (14)

23502

Urology of Virginia-Sentara Medical Group, Norfolk

28204

Carolina's Medical Center / Blumenthal Cancer Center, Charlotte

30322

Emory University, Atlanta

45267

Barrett Cancer, Cincinnati

46202

The Indiana University Cancer Center, Indianapolis

52242

University of Iowa, Iowa City

55455

University of Minnesota Cancer Center, Minneapolis

66160

University of Kansas Hospital, Kansas City

75230

CORTPA, Dallas

80211

The Urology Center of Colorado, Denver

90095

UCLA, Los Angeles

91010

City of Hope, Duarte

M5G2M9

Princess Margaret Hospital, Toronto

H3T1E2

Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Argos Therapeutics

INDUSTRY

NCT00678119 - Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment | Biotech Hunter | Biotech Hunter